

Tae Hyun Kang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6140376/publications.pdf>

Version: 2024-02-01

18
papers

1,039
citations

623734

14
h-index

752698

20
g-index

20
all docs

20
docs citations

20
times ranked

1480
citing authors

#	ARTICLE	IF	CITATIONS
1	Fc Receptor Variants and Disease: A Crucial Factor to Consider in the Antibody Therapeutics in Clinic. International Journal of Molecular Sciences, 2021, 22, 9489.	4.1	4
2	Computer-aided engineering of thermostabilized antibody fragments. AIChE Journal, 2020, 66, e16864.	3.6	12
3	Solubility, Stability, and Avidity of Recombinant Antibody Fragments Expressed in Microorganisms. Frontiers in Microbiology, 2020, 11, 1927.	3.5	43
4	Reprogramming the Constant Region of Immunoglobulin G Subclasses for Enhanced Therapeutic Potency against Cancer. Biomolecules, 2020, 10, 382.	4.0	8
5	An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence. Nature Communications, 2019, 10, 5031.	12.8	49
6	An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIaV158 Reveals That Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages. Frontiers in Immunology, 2019, 10, 562.	4.8	17
7	Boosting therapeutic potency of antibodies by taming Fc domain functions. Experimental and Molecular Medicine, 2019, 51, 1-9.	7.7	77
8	IgG Fc domains that bind C1q but not effector Fcγ3 receptors delineate the importance of complement-mediated effector functions. Nature Immunology, 2017, 18, 889-898.	14.5	122
9	Farewell to Animal Testing: Innovations on Human Intestinal Microphysiological Systems. Micromachines, 2016, 7, 107.	2.9	24
10	Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. Nature Medicine, 2016, 22, 1465-1469.	30.7	104
11	Engineering an aglycosylated Fc variant for enhanced FcγRI engagement and pH-dependent human FcRn binding. Biotechnology and Bioengineering, 2014, 19, 780-789.	2.6	11
12	IgGA: A Cross-Isotype Engineered Human Fc Antibody Domain that Displays Both IgG-like and IgA-like Effector Functions. Chemistry and Biology, 2014, 21, 1603-1609.	6.0	55
13	Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, Aglycosylated IgG Displaying High FcγRIIIa Affinity and Selectivity. ACS Chemical Biology, 2013, 8, 368-375.	3.4	61
14	Revisiting the Role of Glycosylation in the Structure of Human IgG Fc. ACS Chemical Biology, 2012, 7, 1596-1602.	3.4	128
15	Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy. Current Opinion in Biotechnology, 2011, 22, 858-867.	6.6	88
16	Efficient expression and purification of human aglycosylated Fcγ3 receptors in Escherichia coli. Biotechnology and Bioengineering, 2010, 107, 21-30.	3.3	15
17	Aglycosylated IgG variants expressed in bacteria that selectively bind FcγRI potentiate tumor cell killing by monocyte-dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 604-609.	7.1	146
18	Protein Solubility and Folding Enhancement by Interaction with RNA. PLoS ONE, 2008, 3, e2677.	2.5	63